The Final Countdown for New CMS Glycemic Measures: Glytec Prepares Hospitals and Health Systems with Proven, FDA-Cleared Technology Platform

167 Days to Prepare for the New Federal Reporting Requirements for Hypo- and Hyperglycemia

BOSTON, July 17, 2025 /PRNewswire/ -- Glytec is the leading provider of an AI-powered technology platform for diabetes and related conditions, including its FDA-cleared Glucommander® EHR-integrated solution for inpatient glycemic management. Today, Glytec reinforced its commitment to supporting U.S. hospitals in preparation for the upcoming Centers for Medicare & Medicaid Services (CMS) mandate on inpatient glycemic control reporting.

With the measurement period set to begin on January 1, 2026, and just 167 days remaining, now is an important time for hospitals to begin preparing. Equipping teams with the right tools, workflows, and data systems can help ensure readiness for these critical requirements—and avoid potential reductions in Medicare reimbursement starting in fiscal year 2028. Under the new mandate, CMS will require reporting of both severe hypoglycemia (blood glucose <40 mg/dL) and severe hyperglycemia (blood glucose >300 mg/dL) as electronic clinical quality measures (eCQMs). These measures apply to nearly 40% of hospitalized patients who experience dysglycemia during their stay.

"CMS is creating focus and awareness around inpatient diabetes care," said Patrick Cua, CEO of Glytec. "This will help drive improved patient care and patient safety, but hospitals also have revenue to gain via reduced length of stay and cost avoidance through reduced hypoglycemia, lower testing costs, and improved workflows. Glytec's platform is purpose-built to lead hospitals through this transition safely and to continue to innovate around diabetes workflows to drive better patient care and overall economics for healthcare stakeholders."

The new CMS reporting mandate is driven in part by the increasing prevalence of diabetes and its associated complications, which place a significant burden on healthcare systems, payors, and individual lives. More than one-third of hospitalized patients require insulin therapy to manage elevated blood glucose levels during their stay [1]. Each year, more than 2 million patients experience adverse events in the hospital related to hypoglycemia—events that, according to the Agency for Healthcare Research and Quality (AHRQ), contribute to over $8 billion in costs and are associated with increased length of stay and higher readmission rates. Despite the widespread impact of glycemic events, nearly one-third of hospitals do not track glucose management metrics, and 59% lack automated methods to collect data on rates of hyperglycemia and hypoglycemia [2]. In response, some institutions have developed internal solutions, which, while well-intentioned, may introduce challenges related to clinical oversight, regulatory alignment, and the safe management of a high-risk therapy like insulin.

Technology Built for Clinical Excellence and Return on Investment

The Glytec Technology Platform, leveraged by over 400 hospitals, manages complex, high-impact workflows—from hospital to home—with proven results and AI-driven intelligence. It is built on over 100 patents, 100 clinical publications, 16 years of experience, and 50+ billion data points.

As an FDA-cleared platform, Glytec provides:

• Industry superior insulin dosing algorithms with ongoing clinical validation, monitoring, and venture-backed investment
• Real-time dashboards aligned with CMS reporting requirements
• Turn-key EHR integration, enhanced cybersecurity, and reducing IT burden and overhead
• Freedom to operate across the breadth of Glytec's 100+ patented algorithms, workflows, and other intellectual property.

In-House Insulin Tools Fall Short

Some hospitals have explored building their own in-house insulin calculators to manage glycemia, but studies and real-world feedback reveal that these solutions:

• Lack clinical validation, scalability, and rigor of FDA-cleared solutions
• Can introduce user interface challenges and omit clinical guardrails that contribute to dosing errors and patient harm
• Require ongoing maintenance and investment that cannot keep pace with dedicated venture-backed technology companies, and
• Divert critical IT staff from broader strategic hospital technology objectives

167 Days and Counting to Get It Right

The countdown is on. As the CMS mandate nears, hospitals must choose partners to deliver speed, safety, and scale, and avoid the cost, delay, and proven lower outcomes of risky non-regulated approaches.

About Glytec

Glytec's industry-leading technology platform, trusted by over 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay, and optimizing clinical workflows. Its flagship product, Glucommander®—the first-ever FDA-cleared cloud-based insulin management software—integrates seamlessly with EMRs, providing advanced clinical decision support, workflow alerts, patient monitoring, and AI-driven analytics. Supported by over 100 patents and 100 peer-reviewed publications, Glytec is dedicated to improving care from hospital to home. For more information, visit www.glytec.com or follow Glytec on LinkedIn.

Media Contact:

Public Relations
[email protected]

References:

1. Umpierrez GE, et al. Journal of Clinical Endocrinology & Metabolism, 87(3), 978–982. (March 2002). https://doi.org/10.1210/jcem.87.3.8341
2. Cook CB, et al. Endocrine Practice, 16(2), 219–230. (March 2010). https://doi.org/10.4158/EP09234.OR

SOURCE Glytec, LLC